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Replacement of iBAS by beam angle class solutions will be 
discussed as well. 
Conclusion:Automated plan generation, including iBAS, is a 
pre-requisite for systematic, unbiased comparison of the 
impact of beam arrangements in SBRT.  
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Stereotactic Body Radiotherapy (SBRT) involves delivery of a 
high dose with stereotactic precision in only a few fractions. 
Usual treatment sites are lung, liver, spine, prostate and 
often treatment is delivered using a volumetric modulated 
arc therapy (VMAT) technique. With conventional dose rates, 
the highest fraction dose treatments can take 7-12 minutes 
delivery time. This can be reduced to 2-3 minutes by using 
flattening filter free (FFF) beams with dose rates up to 2400 
MU/min. Treatment planning studies have shown similar plan 
quality using FFF or flattened beams. Faster treatments 
implies less time for possible intrafraction motion. However, 
not all measured intrafraction motions could be correlated 
with treatment time. Conversely, due to the fast delivery, 
brief intrafraction shifts may lead to larger dosimetric 
differences than for slower deliveries. In addition, interplay 
effects of a respiratory moving tumor can be larger for the 
faster deliveries. Whether or not all this knowledge can lead 
to margin reduction may also depend on the margins that 
were used and the frequency and accuracy of the imaging. 
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The treatment of cancer with radiopharmaceuticals is 
expanding rapidly in terms of the numbers and range of 
procedures performed. The majority of treatments are 
currently performed with fixed activity administrations, 
sometimes modified according to patient weight or body 
surface area, as  is common practice for chemotherapy 
procedures. Personalised dosimetry-based treatment 
planning, as is routine for external beam radiotherapy 
(EBRT), is now mandated by a new European directive (EU 
directive 2013/59) and presents a number of unique 
challenges. 
There is increasing evidence for strong correlations between 
the absorbed doses delivered to tumours and to organs-at-
risk and response and toxicity (Strigari et al Eur J Nucl Med 
Mol Imaging 2014).  While it is not possible to determine an 
absorbed dose that will be delivered to a tumour or organ 
prior to administration, due to inter-patient variations in 
biokinetics, it is usually found that intra-patient variations 
are much reduced, so that uptake and retention may be 
accurately predicted from a previous therapy study or from a 
tracer study. 
Dosimetry for treatment planning of Molecular Radiotherapy 
(MRT) can be performed with quantitative imaging (SPECT, 
planar or PET) or from external probe measurements. Whole-
body retention measurements allow the calculation of whole-
body dosimetry which, as a surrogate for bone marrow 
dosimetry, has been used for several therapy procedures 
including I-131 mIBG treatment of neuroblastoma in 
paediatrics, uptake measurements for the treatment of 
benign thyroid disease with radioiodine and 
radioimmunotherapy for NHL. Dosimetry based on organ 
dosimetry has been less utilised, although the absorbed doses 
delivered to kidneys are recognised as a limiting factor in 
peptide receptor radionuclide therapy. 
The role of treatment planning is of particular relevance to 
an emerging cohort of commercially driven radiotherapeutics 
and has attracted conflicting approaches. The treatment of 
HCC and liver metastases with intra-arterial injections of 
radiolabelled microspheres has been developed for Y-90 and 
Ho-166 resin and glass microspheres. Initial treatment 
protocols were based on body surface area, although have 
become increasingly sophisticated. Two industry sponsored 
multi-centre international studies are currently in 
preparation to ascertain the correlation of the absorbed 
doses with response on which future treatments would be 
based. Conversely, Ra-223 has recently been at the forefront 
of a new wave of alpha based therapies, although is currently 
administered as a chemotherapeutic with a series of six 
weight-based administrations at 4 week intervals. 
A number of challenges are to be addressed as prospective 
treatment planning is introduced. Tracer administrations I-
131 NaI are considered to cause a ‘stunning’ effect whereby 
further uptake of a therapeutic administration is mitigated, 
although as yet there are no systematic studies to 
demonstrate this effect or its severity. Further, the %ID of 
uptake from a tracer administration will not necessarily 
predict the uptake of a therapeutic administration that may 
be two orders of magnitude higher. This may entail the 
application of correction factors. Further issues to be 
resolved are that patient-specific factors, that may include 
considerations of previous treatments or the time to recovery 
of marrow depression, preclude rigid protocols that will 
necessarily be targeted to the most vulnerable of patients 
and will therefore be sub-optimal for the majority. 
In conclusion, as outstanding challenges are addressed and 
resolved, the ability to directly image the uptake and 
retention of a radiotherapeutic in vivo and the adoption of 
treatment schedules that allow time between sequential 
administrations to calculate the absorbed doses delivered 
and to modify further treatments accordingly, offer the 
potential for highly personalised treatment planning for MRT 
that can only lead to improved efficacy. 
   
SP-0368   
Combined forces: Radium-223 + IMRT in the fight to cure 
metastatic prostate cancer 
J.M. O'Sullivan1 
1Queen's University Belfast, Centre for Cancer Research & 
Cell Biology, Belfast, United Kingdom  
 
Bone metastases are a frequent consequence from a wide 
range of malignancies and are associated with a high degree 
of morbidity. More than 90% of patients with metastatic 
castrate resist-ant prostate cancer (mCRPC) have bone 
metastases, often as the only significant metastatic site [1]. 
At diagnosis, approximately10-15% of men presenting with 
prostate cancer have bone metastases at diagnosis. These 
